{"id":"NCT04508621","sponsor":"Tonix Pharmaceuticals, Inc.","briefTitle":"A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia","officialTitle":"A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-22","primaryCompletion":"2021-11-01","completion":"2021-11-01","firstPosted":"2020-08-11","resultsPosted":"2022-12-02","lastUpdate":"2023-12-18"},"enrollment":514,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"TNX-102 SL","otherNames":["Low dose cyclobenzaprine sublingual tablets"]},{"type":"DRUG","name":"Placebo SL Tablet","otherNames":["Placebo sublingual tablets"]}],"arms":[{"label":"TNX-102 SL Tablet, 5.6 mg","type":"EXPERIMENTAL"},{"label":"Placebo SL Tablet","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.","primaryOutcome":{"measure":"Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.","timeFrame":"14 weeks","effectByArm":[{"arm":"TNX-102 SL Tablet, 5.6 mg","deltaMin":-1.6,"sd":null},{"arm":"Placebo SL Tablet","deltaMin":-1.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.115"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":256},"commonTop":["Hypoaesthesia oral","Product taste abnormal","Oral discomfort","Tongue discomfort"]}}